A carregar...
Cholestatic Liver Injury Induced by Pembrolizumab in a Patient with Lung Adenocarcinoma
The anti-programmed cell death-1 protein monoclonal antibody, pembrolizumab is an immune checkpoint inhibitor. While it improves the prognoses of patients with advanced non-small-cell lung cancer, it has been reported to induce various kinds of immune-related adverse events, including hepatotoxicity...
Na minha lista:
| Publicado no: | Intern Med |
|---|---|
| Main Authors: | , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
The Japanese Society of Internal Medicine
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6911765/ https://ncbi.nlm.nih.gov/pubmed/31735738 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2169/internalmedicine.2591-18 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|